Baxalta Inc (BXLT) : Harvest Management scooped up 117,600 additional shares in Baxalta Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 11, 2016. The investment management firm now holds a total of 146,000 shares of Baxalta Inc which is valued at $6.2 Million.Baxalta Inc makes up approximately 7.67% of Harvest Management’s portfolio.
Other Hedge Funds, Including , Artemis Investment Management Llp sold out all of its stake in BXLT during the most recent quarter. The investment firm sold 218,400 shares of BXLT which is valued $9.3 Million.Stratos Wealth Partners Ltd. reduced its stake in BXLT by selling 519 shares or 4.31% in the most recent quarter. The Hedge Fund company now holds 11,512 shares of BXLT which is valued at $487,994. Baxalta Inc makes up approx 0.04% of Stratos Wealth Partners Ltd.’s portfolio. Global X Management Co added BXLT to its portfolio by purchasing 322 company shares during the most recent quarter which is valued at $13,257.
Baxalta Inc opened for trading at $42.33 and hit $42.89 on the upside on Monday, eventually ending the session at $42.82, with a gain of 1.01% or 0.43 points. The heightened volatility saw the trading volume jump to 1,22,43,940 shares. Company has a market cap of $29,269 M.
On the company’s financial health, Baxalta Inc reported $0.47 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $0.46. The company had revenue of $1548.00 million for the quarter, compared to analysts expectations of $1474.42 million. The company’s revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.40 EPS.
Baxalta Incorporated is a biopharmaceutical company. The Company develops manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders immune deficiencies alpha-1 antitrypsin deficiency burns and shock and other chronic and acute medical conditions. The Company also focuses on disease areas including oncology as well as technology platforms including gene therapy and biosimilars. The Company has a portfolio of various therapies that address unmet medical needs across various disease areas including hemophilia immunology and oncology. The Company’s products include ADVATE RECOMBINATE HEMOFIL M Immunate Immunine PROTHROMPLEX TOTAL RIXUBIS FACTOR VII NF BEBULIN FEIBA OBIZUR GAMMAGARD LIQUID GAMMAGARD S/D Subcuvia HYQVIA FLEXBUMIN BUMINATE ARALAST NP GLASSIA NP CEPROTIN and ANTITHROMBIN III IMMUNO.